Tiziana Life Sciences

Tiziana Life Sciences is a NASDAQ-listed clinical-stage biotechnology company which pays close attention to transformational technology enabling alternative methods for immunotherapy. This company has reactivated its strategic plan to redomicile to Bermuda during the operation.

Tiziana Life Sciences specialises in building up a variety of transformative therapies for neurodegenerative and lung diseases. The clinical system of this company consists of drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. With the mission to bring breakthrough therapies to patients, this organization hopes to treat Secondary Progressive Multiple Sclerosis, ALS, Alzheimer's, and other CNS indications. Crohn's Disease, lung diseases and optimize health outcomes. Particularly, highly qualified executives lead Tiziana Life Sciences with extensive drug development and commercialization experience.

Tiziana Life Sciences is fostering transformational formulation technologies, enabling to switch from traditional routes to alternative ones of immunotherapy to simplify local sites of action. This can be exemplified by nasal, oral and inhalation administrations that target neurodegenerative and lung diseases. On top of that, this company always believe that employees have the potential to alter the way immunotherapies are currently conducted.

Founded: 1998

Location: Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda

Website: https://www.tizianalifesciences.com/